JW Therapeutics (HKEX: 02126) reported no movements in either authorised or issued share capital for the month ended 31 July 2026. Authorised capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001, equivalent to US$50,000. Issued shares were unchanged at 416.73 million, and the company held no treasury stock.

The public-float level continued to satisfy the Main Board’s 25% threshold.

Equity incentive obligations were unchanged: • Stock options: 22.77 million options outstanding across 14 grants—comprising both pre-IPO and post-IPO schemes—with exercise prices ranging from US$0.00001 to HK$16.20. • Restricted share units: a further 1.20 million shares may be issued under the 2019 RSU scheme.

If all outstanding options and RSUs were exercised or vested, the potential dilution would represent roughly 5.75% of the current share base.

No warrants, convertibles, or other share-related instruments were issued or redeemed during the period, and no funds were raised from equity exercises. Feng Tian, Executive Director, confirmed compliance with all Hong Kong listing and regulatory requirements.